InnoCare Pharma Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INCPF research report →
Price Chart
About the company
InnoCare Pharma Limited is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments, primarily targeting cancer and autoimmune disorders. A key product in their portfolio is Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. This therapy targets various relapsed or refractory blood cancers, including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, diffuse large B-cell lymphoma (MCD subtype), central nervous system lymphoma, and is also being explored in combination with MIL-62.
- CEO
- Jisong Cui
- IPO
- 2021
- Employees
- 1,089
- HQ
- Beijing, BE, CN
Get TickerSpark's AI analysis on INCPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.32B
- P/E
- 30.55
- Fwd P/E
- 20.55
- PEG
- 0.07
- P/S
- 7.31
- P/B
- 2.95
- EV/EBITDA
- 20.72
- Div Yield
- 0.00%
- Gross Margin
- 90.36%
- Op Margin
- 23.70%
- Net Margin
- 28.78%
- ROE
- 10.12%
- ROIC
- 6.18%
Latest fiscal year · YoY change
- Revenue
- $2.30B+127.6%
- Gross Profit
- $2.01B+131.1%
- Op Income
- $440.63M
- Net Income
- $625.89M+242.0%
- EPS
- $0.36+238.5%
- OCF Growth
- +154.5%
- FCF Growth
- +129.5%
- 52W High
- $3.26
- 52W Low
- $1.55
- 50D MA
- $1.55
- 200D MA
- $1.75
- Beta
- 0.39
- RSI (14)
- 0
- Avg Volume
- 779
No earnings-call transcripts are available for INCPF yet.
- Free Float
- 78.7%
- Shares Outstanding
- 1.49B
- Float Shares
- 1.18B
Our INCPF coverage
Recent articles, reports, and earnings notes.
No research on INCPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INCPF report →China's Innocare's psoriasis drug meets main goal in late-stage trial
reuters.com · Jul 27
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
globenewswire.com · Jul 5
Phase IIb Study Results of InnoCare's Orelabrutinib in Patients with SLE Presented at 2026 EULAR
globenewswire.com · Jun 5
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
globenewswire.com · Jun 2
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
globenewswire.com · May 28
InnoCare Announces Approval of Orelabrutinib in Australia
globenewswire.com · May 27
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
globenewswire.com · May 22
InnoCare Announce First Subject Dosed in Phase 1 Clinical Trial of ICP-054, a Novel Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
globenewswire.com · May 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.